15-SORRENTO-Therapeutics-Logo-FINAL.png
Sorrento Therapeutics Expands Resiniferatoxin (RTX) Clinical Development Program to Life-Threatening Cardiovascular Diseases With Completion of Major Animal Toxicology Study
15 avr. 2019 04h00 HE | Sorrento Therapeutics, Inc.
SAN DIEGO, April 15, 2019 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (NASDAQ: SRNE, "Sorrento"), announced that its Neuro-Therapeutics unit is pursuing clinical development of resiniferatoxin...
IMC Logo.jpg
Immuron Aims to Secure FDA Approval for IMM-124E to Prevent Travelers’ Diarrhea
11 avr. 2019 09h00 HE | Immuron Limited
Key Points Immuron to develop U.S. registration dossier for IMM-124E for Travelers’ DiarrheaCompany anticipates significant inflection in sales with successful FDA registration of IMM-124ECompany to...
hemostemix-logo-small.jpg
Hemostemix Announces Enrollment Milestone in the ACP-01 Phase II Critical Limb Ischemia Clinical Trial
09 avr. 2019 08h30 HE | Hemostemix Inc.
CALGARY, Alberta, April 09, 2019 (GLOBE NEWSWIRE) -- Hemostemix Inc. (“Hemostemix” or the “Company”) (TSX VENTURE: HEM; OTCQB: HMTXF) is pleased to announce that it has reached an enrollment...
Logo-uniQure-MS-Word_Orange.jpg
uniQure Receives FDA Fast Track Designation for AMT-130 Gene Therapy for the Treatment of Huntington’s Disease
08 avr. 2019 07h00 HE | uniQure Inc.
LEXINGTON, Mass. and AMSTERDAM, the Netherlands, April 08, 2019 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with...
jpg.jpg
Incycus Therapeutics Appoints Melissa Beelen as Vice President, Clinical Operations
03 avr. 2019 08h00 HE | Incysus Therapeutics, Inc.
NEW YORK, April 03, 2019 (GLOBE NEWSWIRE) -- Incysus Therapeutics, Inc. (“Incysus”), a biopharmaceutical company focused on delivering an innovative gamma-delta (γδ) T cell immunotherapy for the...
physeon.png
Physeon Positive Clinical Trial Results for its Veinplicity® Device to be Published in The Journal of Vascular Access
01 avr. 2019 09h00 HE | Physeon
SCHAFFHAUSEN, Switzerland, April 01, 2019 (GLOBE NEWSWIRE) -- Physeon GmbH, (“Physeon” or the “Company”), a leading developer of medical technology products for venous access, today announced that...
axsomelogo-468x57.jpg
Axsome Therapeutics Receives FDA Breakthrough Therapy Designation for AXS-05 for the Treatment of Major Depressive Disorder
27 mars 2019 07h00 HE | Axsome Therapeutics, Inc.
Designation offers potential for expedited development and review NEW YORK, March 27, 2019 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a clinical-stage biopharmaceutical company...
CURE Logo.png
CURE Pharmaceutical Announces Completion of FDA Pre-IND Review and Clinical Trial Plans for CUREfilm Blue™ for Erectile Dysfunction
26 mars 2019 07h25 HE | Cure Pharmaceutical Holding Corp.
OXNARD, Calif., March 26, 2019 (GLOBE NEWSWIRE) -- CURE Pharmaceutical (OTC: CURR), an innovative drug delivery and development company, today announced it has successfully completed a pre-IND...
ExCellThera_RGB.png
ExCellThera announces clearance by FDA and Health Canada for ECT-001 in new clinical trials in United States and Canada for the treatment of leukemia
25 mars 2019 08h07 HE | ExCellThera
MONTREAL, March 25, 2019 (GLOBE NEWSWIRE) -- ExCellThera Inc., a clinical stage biotechnology company delivering molecules and bioengineering solutions to expand stem and immune cells for...
CBD Logo.png
Update:  CBD Unlimited Announces Completion of Product Label Review and Vendor Applications for Entrance into Pharmacy, Food, and Mass Retail
18 mars 2019 11h50 HE | CBD Unlimited, Inc.
CAVE CREEK, AZ, March 18, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- CBD Unlimited, Inc. formerly known as Endexx Corporation (EDXC), a provider of innovative phytonutrient-based food and...